Traders should monitor for preliminary data in H2 2026, which could drive significant volatility. The prior Phase 1/2 data provides some de-risking, but the Phase 2 readout is the key catalyst. Given the $55M market cap, positive data could lead to a multi-bagger, while negative data could severely impair the stock. Consider position sizing accordingly.
Price Chart
Executive Summary
MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT cell therapy agenT-797 in patients with acute lung injury and hypoxemic respiratory failure. The study, conducted in partnership with First Lviv Medical Union and UNBROKEN Ukraine, targets a large unmet need with no approved therapies, and preliminary data are expected in H2 2026. For a $55M market cap clinical-stage biotech, this represents a significant pipeline catalyst with potential to unlock a new indication beyond oncology.
Key Facts
- Randomized Phase 2 trial (C-1300-02) initiated for agenT-797 in acute lung injury (ALI) with hypoxemic respiratory failure.
- Study is placebo-controlled, evaluating survival, ventilator-free days, and secondary infections; preliminary data expected H2 2026.
- AgenT-797 is an off-the-shelf allogeneic iNKT cell therapy, enabling rapid deployment in critical care without patient-specific manufacturing.
- Prior Phase 1/2 data (Hammond et al., Nat Comms) showed improved survival and reduced secondary infections in virally induced ARDS.
- Partnership with First Lviv Medical Union and UNBROKEN Ukraine provides access to a high-acuity patient population; U.S. sites being added.
- ALI/ARDS affects ~200,000 patients annually in the U.S. with no approved mortality-reducing therapies.
- MiNK market cap is ~$55M, making this a high-risk/high-reward catalyst for a small-cap biotech.
Financial Impact
No financial data provided; trial is early-stage with no revenue or deal value disclosed. Potential upside is binary based on H2 2026 data readout.
Risk Factors
- Clinical trial failure: Phase 2 may not replicate prior Phase 1/2 signals.
- Regulatory uncertainty: No approved therapies exist for ARDS; path to approval is unproven.
- Execution risk: Trial in Ukraine faces geopolitical and operational challenges.
- Cash runway: As a clinical-stage company, MiNK may need to raise capital before data readout.
- Competition: Other immune-modulating therapies in development for ARDS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294797 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access